Lymphomas are a field of constant research, where new medicines have an important place. Associating complementary expertise in lymphoma research, the Lymphoma Research Experts ecosystem works on many new avenues every year.
Examples of treatments under study:
- New chemotherapies, which are currently not very numerous
- New antibodies against the CD20 antigen, especially obinotuzumab or GA101
- Antibodies associated with toxins, also called immunotoxins or immunoconjugates.
- Histone deacetylase inhibitors (HDAC), which are medicines that act on the genetic material structure and are being studied especially for T-cell lymphomas (romidepsin in particular)
- Targeted therapies that act on the abnormal mechanisms of the lymphoma cells (certain targeted therapies, such as bortezomib, are already used for other blood diseases)
- Immunomodulatory medicines, such as lenalidomide, which is already frequently used against myelomas and which could act alone or combined with chemotherapy or rituximab for certain types of lymphoma.